Track topics on Twitter Track topics that are important to you
Cellfree DNA are small fragments of DNA circulating freely in the blood and body fluids which are utilized as a valuable biomarker to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of gynecology, oncology, transplantation and infectious diseases. The cellfree DNA testing global market is segmented based on the type, applications and geography. By type the market is divided into cellfree fetal DNA, circulating tumour DNA, Donor derived cellfree DNA. By application, the Cellfree DNA testing market is divided into gynecology, oncology, and transplantation.
Among the Cellfree DNA testing market by test type, the cellfree fetal DNA testing market is dominating the market by occupying a largest share of XX%. The donor DNA product is expected to launch in 2017 hence CAGR is calculated from 201720122 which makes it the fastest growing segment with CAGR XX%. In applications, the gynecology holds the largest segment with XX% share and transplantation is the fastest growing segment with a CAGR of XX% from 2017 to 2022. Geographical wise, North America holds the largest market, with a share of XX% followed by Europe and Asia. The APAC region is the fastest growing region with a CAGR of XX% from 2015 to 2022 suggesting an array of opportunities for growth and likely to be getting into the eyes of new investors in the cellfree DNA testing market. Growth in the Asian market is attributed to rising prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
The cellfree DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022. The factors driving the growth of this market are raising number of late pregnancies leading to high incidence rates of babies with chromosomal disorders, increasing number of life threatening cancer and infectious diseases are likely to propel the market. In addition, increasing demand for early detection through noninvasive testing procedures, healthy growth with increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to genetic testing, lack of standardization, high cost and non affordability in low and middleincome countries, unfavourable reimbursement policies and strict legal and regulatory guidelines are hampering the growth of the market. The threats for the Cellfree DNA testing market include the availability of alternative screening methods which will impact the existing market.
The cellfree DNA testing global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the cellfree DNA testing market include Berry Genomics Co. Ltd China, BGI China, Boreal Genomics U.S, Guardant health, IncU.S, Inivata Limited U.K, Illumina, Inc.U.S., Laboratory Corp. of America Holdings U.S., Lifecodexx AG Germany, Natera, Inc. U.S., Personal Genome Diagnostics U.S, Premaitha Health U.K., Quest Diagnostics U.S., Roche Holdings AG Switzerland, Sequenom, Inc. U.S., Trovagene, Inc U.S etc.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
Rest of the World RoW
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...